1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. CDK
  4. CDK2 Inhibitors

CDK2 Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform CDK2 together.

Please try each isoform separately.

CDK2 Specific Inhibitors & Antagonists
Product Name CDK2 CDK1 CDK3 CDK4 CDK5 CDK6 CDK7 CDK9 CDK14 CDK16 CDK2 Selectivity Purity
CDK2-IN-4
cdk2/cyclin A, IC50: 44 nM
Cdk1/cyclin B, IC50: 86 μM
                Selective Inhibitor >97.0%
AUZ 454
CDK2(C118L/A144C), Kd: 9.7 nM
CDK2(A144C), Kd: 15.4 nM
CDK2(C118L), Kd: 18.6 nM
CDK2(WT), Kd: 50 nM
CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM
                  Selective Inhibitor 99.99%
NU6300
CDK2, IC50: 0.16 μM
                  Selective Inhibitor 97.03%
BGG463
CDK2
                  Selective Inhibitor >98.0%
Desmethylglycitein
CDK2
CDK1
                Selective Inhibitor
Abemaciclib methanesulfonate
CDK2/cyclinE, IC50: 504 nM
CDK1/cyclinB1, IC50: 1627 nM
 
Cdk4/cyclin D1, IC50: 2 nM
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
CDK9/cyclinT1, IC50: 57 nM
    Pan Inhibitor 99.95%
Dinaciclib
CDK2, IC50: 1 nM
CDK1, IC50: 3 nM
   
CDK5, IC50: 1 nM
   
CDK9, IC50: 4 nM
    Pan Inhibitor 99.73%
Seliciclib
cdk2/cyclin A, IC50: 0.7 μM
Cdk2/cyclin E2, IC50: 0.7 μM
cdc2/cyclin B, IC50: 0.65 μM
   
CDK5/p35, IC50: 0.16 μM
          Pan Inhibitor 99.94%
Flavopiridol
CDK2/Cyc E, IC50: 170 nM
CDK1/Cyc B1, IC50: 30 nM
 
CDK4/Cyc D1, IC50: 100 nM
            Pan Inhibitor 99.72%
Ro-3306
CDK2/cyclinE, Ki: 340 nM
CDK1, Ki: 20 nM
CDK1/cyclinB1, Ki: 35 nM
CDK1/cyclin A, Ki: 110 nM
                Pan Inhibitor 96.77%
Abemaciclib
CDK2/cyclinE, IC50: 504 nM
CDK1/cyclinB1, IC50: 1627 nM
 
Cdk4/cyclin D1, IC50: 2 nM
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
CDK6/cyclinD1, IC50: 10 nM
CDK7/Mat1/cyclinH1, IC50: 3910 nM
CDK9/cyclinT1, IC50: 57 nM
    Pan Inhibitor 99.69%
CYC065
CDK2
           
CDK9
    Pan Inhibitor 99.78%
PF-06873600
CDK2, Ki: 0.09 nM
   
CDK4, Ki: 0.13 nM
 
CDK6, Ki: 0.16 nM
        Pan Inhibitor 99.98%
SNS-032
CDK2, IC50: 38 nM
CDK1, IC50: 480 nM
 
CDK4, IC50: 925 nM
   
CDK7, IC50: 62 nM
CDK9, IC50: 4 nM
    Pan Inhibitor 98.50%
CT7001 hydrochloride
CDK2/cycE1, IC50: 578 nM
         
CDK7/CycH/MAT1, IC50: 41 nM
      Pan Inhibitor 99.98%
AZD-5438
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
cdk1-cyclin B1, IC50: 16 nM
 
cdk4-cyclin D1, IC50: 449 nM
cdk5-p25, IC50: 14 nM
cdk6-cyclin D3, IC50: 21 nM
cdk7-cyclin H, IC50: 821 nM
cdk9-cyclin T, IC50: 20 nM
    Pan Inhibitor 99.37%
AT7519
cdk2/cyclin A, IC50: 47 nM
Cdk1/cyclin B, IC50: 210 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
CDK9/Cyclin T, IC50: 10 nM
    Pan Inhibitor 98.15%
CVT-313
cdk2/cyclin A, IC50: 0.5 μM
Cdk1/cyclin B, IC50: 4.2 μM
 
Cdk4/cyclin D1, IC50: 215 μM
            Pan Inhibitor 99.76%
JNJ-7706621
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
Cdk1/cyclin B, IC50: 9 nM
CDK3/Cyclin E, IC50: 58 nM
Cdk4/cyclin D1, IC50: 253 nM
 
CDK6/cyclinD1, IC50: 175 nM
        Pan Inhibitor 99.91%
GSK 3 Inhibitor IX
cdk2/cyclin A, IC50: 300 nM
Cdk1/cyclin B, IC50: 320 nM
 
Cdk4/cyclin D1, IC50: 10 μM
CDK5/p35, IC50: 80 nM
          Pan Inhibitor 99.66%
Milciclib
cyclin A/CDK2, IC50: 45 nM
cyclin E/CDK2, IC50: 363 nM
cyclin B/CDK1, IC50: 398 nM
 
cyclin D1/CDK4, IC50: 160 nM
   
cyclin H/CDK7, IC50: 150 nM
      Pan Inhibitor 98.61%
PHA-767491 hydrochloride
CDK2, IC50: 240 nM
CDK1, IC50: 250 nM
   
CDK5, IC50: 460 nM
   
CDK9, IC50: 34 nM
    Pan Inhibitor 99.91%
LDC000067
cdk2-cyclin A, IC50: 2441 nM
cdk1-cyclin B1, IC50: 5513 nM
 
cdk4-cyclin D1, IC50: 9242 nM
     
CDK9- Cyclin T1, IC50: 44 nM
    Pan Inhibitor 98.14%
Purvalanol A
cdk2-cyclin E, IC50: 35 nM
cdk2-cyclin A, IC50: 70 nM
cdc2-cyclin B, IC50: 4 nM
 
cdk4-cyclin D1, IC50: 850 nM
cdk5-p35, IC50: 75 nM
          Pan Inhibitor 98.66%
CDKI-73
CDK2, IC50: 3.27 nM
CDK1, IC50: 8.17 nM
 
CDK4, IC50: 8.18 nM
 
CDK6, IC50: 37.68 nM
CDK7, IC50: 134.26 nM
CDK9, IC50: 5.78 nM
    Pan Inhibitor 99.58%
R547
CDK2/cyclinE, Ki: 3 nM
Cdk1/cyclin B, Ki: 2 nM
 
CDK4/cyclin D, Ki: 1 nM
            Pan Inhibitor 98.42%
BMS-265246
CDK2/Cyc E, IC50: 9 nM
CDK1/cycB, IC50: 6 nM
 
CDK4/cycD, IC50: 230 nM
            Pan Inhibitor 97.47%
Atuveciclib
CDK2/CycE(h), IC50: 1000 nM
CDK1/CycB(h), IC50: 1100 nM
CDK3/CycE(h), IC50: 890 nM
 
CDK5/p35(h), IC50: 1600 nM
   
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
    Pan Inhibitor 99.42%
Flavopiridol Hydrochloride
CDK2/Cyc E, IC50: 170 nM
CDK1/Cyc B1, IC50: 30 nM
 
CDK4/Cyc D1, IC50: 100 nM
            Pan Inhibitor 99.74%
AT7519 Hydrochloride
cdk2/cyclin A, IC50: 47 nM
Cdk1/cyclin B, IC50: 210 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
CDK9/Cyclin T, IC50: 10 nM
    Pan Inhibitor 99.99%
SU9516
CDK2, IC50: 22 nM
CDK1, IC50: 40 nM
 
CDK4, IC50: 200 nM
            Pan Inhibitor 99.76%
Lerociclib dihydrochloride
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
CDK1/cyclinB1, IC50: 2.4 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
CDK9/Cyclin T, IC50: 28 nM
    Pan Inhibitor 98.45%
MC180295
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
CDK1-Cyclin B, IC50: 138 nM
CDK3-Cyclin E, IC50: 399 nM
CDK4-Cyclin D, IC50: 112 nM
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
cdk6-cyclin D3, IC50: 712 nM
CDK7-CycH/MAT1, IC50: 555 nM
CDK9- Cyclin T1, IC50: 5 nM
    Pan Inhibitor 98.47%
Purvalanol B
cdk2/cyclin A, IC50: 6 nM
CDK2/cyclinE, IC50: 9 nM
cdc2/cyclin B, IC50: 6 nM
cyclin dependent kinase 1-cyclinB, IC50: 6 nM
 
Cdk4/cyclin D1, IC50: 10000 nM
CDK5/p35, IC50: 6 nM
          Pan Inhibitor >97.0%
FN-1501
cdk2/cyclin A, IC50: 2.47 nM
   
Cdk4/cyclin D1, IC50: 0.85 nM
 
CDK6/cyclinD1, IC50: 1.96 nM
        Pan Inhibitor 98.41%
AMG 925
CDK2, IC50: 375 nM
CDK1, IC50: 1.9 μM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
        Pan Inhibitor 99.33%
JSH-150
cdk2/cyclin A, IC50: 2.86 μM
Cdk1/cyclin B, IC50: 1.34 μM
   
Cdk5/p25, IC50: 4.64 μM
 
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
CDK9/cyclinT1, IC50: 1 nM
CDK14/Cyclin Y, IC50: 1.68 μM
CDK16/Cyclin Y, IC50: 292 nM
Pan Inhibitor 92.04%
NVP-LCQ195
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
Cdk1/cyclin B, IC50: 2 nM
CDK3/Cyclin E, IC50: 42 nM
 
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
cdk6/cyclin D3, IC50: 187 nM
CDK7/Cyclin H/MAT1, IC50: 3564 nM
CDK9/cyclinT1, IC50: 15 nM
    Pan Inhibitor 98.99%
Alsterpaullone
cdk2/cyclin A, IC50: 15 nM
CDK2/Cyc E, IC50: 200 nM
Cdk1/cyclin B, IC50: 35 nM
   
CDK5/p35, IC50: 40 nM
          Pan Inhibitor 97.30%
NU2058
CDK2, IC50: 17 μM
CDK1, IC50: 26 μM
                Pan Inhibitor 99.01%
AT7519 trifluoroacetate
cdk2/cyclin A, IC50: 47 nM
Cdk1/cyclin B, IC50: 210 nM
 
Cdk4/cyclin D1, IC50: 100 nM
CDK5/p35, IC50: 13 nM
cdk6/cyclin D3, IC50: 170 nM
CDK7/Cyclin H/MAT1, IC50: 2400 nM
CDK9/Cyclin T, IC50: 10 nM
    Pan Inhibitor 98.16%
PHA-767491
CDK2, IC50: 240 nM
CDK1, IC50: 250 nM
   
CDK5, IC50: 460 nM
   
CDK9, IC50: 34 nM
    Pan Inhibitor
AMG 925 HCl
CDK2, IC50: 375 nM
CDK1, IC50: 1.9 μM
 
CDK4, IC50: 3 nM
 
CDK6, IC50: 8 nM
        Pan Inhibitor 98.01%
Roniciclib
CDK2/cyclinE, IC50: 9 nM
Cdk1/cyclin B, IC50: 7 nM
 
CDK4/cyclin D, IC50: 11 nM
   
CDK7/Cyclin H/MAT1, IC50: 25 nM
CDK9/cyclinT1, IC50: 5 nM
    Pan Inhibitor
BS-181 hydrochloride
CDK2/Cyc E, IC50: 0.88 μM
CDK1/cycB, IC50: 8.1 μM
 
CDK4/Cyc D1, IC50: 33 μM
CDK5/p35NCK, IC50: 3 μM
CDK6/cycD1, IC50: 47 μM
CDK7/CycH/MAT1, IC50: 0.021 μM
CDK9/cycT, IC50: 4.2 μM
    Pan Inhibitor
FMF-04-159-2
CDK2, IC50: 256 nM (in NanoBRET assay)
             
CDK14/Cyclin Y, IC50: 39.6 nM (in NanoBRET assay)
  Pan Inhibitor 99.34%
Riviciclib hydrochloride
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
CDK1-Cyclin B, IC50: 0.079 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
 
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
    Pan 98.33%
IIIM-290
CDK2/A, IC50: 90 nM
           
CDK9/T1, IC50: 94 nM
    Pan Inhibitor
Riviciclib
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
CDK1-Cyclin B, IC50: 0.079 μM
 
cdk4-cyclin D1, IC50: 0.063 μM
 
cdk6-cyclin D3, IC50: 0.396 μM
 
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
    Pan Inhibitor
Bisindolylmaleimide X hydrochloride
CDK2, IC50: 200 nM
                  Pan Antagonist 98.53%
NU6140
cdk2-cyclin A, IC50: 0.41 μM
CDK1-Cyclin B, IC50: 6.6 μM
 
CDK4-Cyclin D, IC50: 5.5 μM
cdk5-p25, IC50: 15 μM
 
cdk7-cyclin H, IC50: 3.9 μM
      Pan Inhibitor >99.0%
Lerociclib
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
CDK1/cyclinB1, IC50: 2.4 μM
 
Cdk4/cyclin D1, IC50: 1 nM
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
cdk6/cyclin D3, IC50: 2 nM
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
CDK9/Cyclin T, IC50: 28 nM
    Pan Inhibitor
Indirubin-5-sulfonate
cdk2/cyclin A, IC50: 35 nM
CDK2/cyclinE, IC50: 150 nM
Cdk1/cyclin B, IC50: 55 nM
 
Cdk4/cyclin D1, IC50: 300 nM
CDK5/p35, IC50: 65 nM
          Pan Inhibitor